Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Andrew S. Chi, M.D., Ph.D.

TitleAssistant Professor of Neurology
InstitutionMassachusetts General Hospital
DepartmentNeurology
AddressMassachusetts General Hospital
Yawkey 9E, Neuro-oncology
55 Fruit St
Boston MA 02114

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
    View in: PubMed
  2. Chi AS, Chamberlain MC. Is there a role for bevacizumab in the treatment of glioblastoma? Oncologist. 2013; 18(10):1080-2.
    View in: PubMed
  3. Muise ES, Souza S, Chi A, Tan Y, Zhao X, Liu F, Dallas-Yang Q, Wu M, Sarr T, Zhu L, Guo H, Li Z, Li W, Hu W, Jiang G, Paweletz CP, Hendrickson RC, Thompson JR, Mu J, Berger JP, Mehmet H. Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS One. 2013; 8(9):e73011.
    View in: PubMed
  4. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013 Sep 3; 123(9):3659-63.
    View in: PubMed
  5. Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
    View in: PubMed
  6. Taylor JW, Chi AS, Cahill DP. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management. Oncology (Williston Park). 2013 Jun; 27(6):504-14.
    View in: PubMed
  7. Rheinbay E, SuvĂ  ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE. An aberrant transcription factor network essential for wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013 May 30; 3(5):1567-79.
    View in: PubMed
  8. Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN. BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults. J Clin Oncol. 2013 May 10; 31(14):e233-6.
    View in: PubMed
  9. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
    View in: PubMed
  10. Chi AS, Wen PY. Inhibiting angiogenesis in malignant gliomas. Handb Clin Neurol. 2012; 104:279-308.
    View in: PubMed
  11. Chi AS, Batchelor TT, Kwak EL, Clark JW, Wang DL, Wilner KD, Louis DN, Iafrate AJ. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol. 2012 Jan 20; 30(3):e30-3.
    View in: PubMed
  12. Coumans JV, Walcott BP, Nahed BV, Oh KS, Chi AS. Multimodal therapy of an intramedullary cervical primitive neuroectodermal tumor in an adult. J Clin Oncol. 2012 Jan 10; 30(2):e15-8.
    View in: PubMed
  13. Paweletz CP, Andersen JN, Pollock R, Nagashima K, Hayashi ML, Yu SU, Guo H, Bobkova EV, Xu Z, Northrup A, Blume-Jensen P, Hendrickson RC, Chi A. Identification of direct target engagement biomarkers for kinase-targeted therapeutics. PLoS One. 2011; 6(10):e26459.
    View in: PubMed
  14. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol. 2012 Mar; 107(1):133-8.
    View in: PubMed
  15. Mendenhall EM, Koche RP, Truong T, Zhou VW, Issac B, Chi AS, Ku M, Bernstein BE. GC-rich sequence elements recruit PRC2 in mammalian ES cells. PLoS Genet. 2010; 6(12):e1001244.
    View in: PubMed
  16. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010 Aug 4; 2(43):43ra55.
    View in: PubMed
  17. Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N, Altman N. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 2010 Apr 1; 70(7):2613-23.
    View in: PubMed
  18. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, Lutterbach BA, Paweletz CP, Qu X, Reilly JF, Szewczak AA, Zeng Q, Kohl NE, Dinsmore CJ. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15; 70(4):1524-33.
    View in: PubMed
  19. Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics. 2009 Jul; 6(3):513-26.
    View in: PubMed
  20. Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009 Jun; 14(6):621-36.
    View in: PubMed
  21. Chi AS, Bernstein BB. Pluripotent chromatin state. Science. 2009; 323(5911):220-1.
  22. Chi AS, Bernstein BE. Developmental biology. Pluripotent chromatin state. Science. 2009 Jan 9; 323(5911):220-1.
    View in: PubMed
  23. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, Presser A, Nusbaum C, Xie X, Chi AS, Adli M, Kasif S, Ptaszek LM, Cowan CA, Lander ES, Koseki H, Bernstein BE. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet. 2008 Oct; 4(10):e1000242.
    View in: PubMed
  24. Chi AS, Batchelor TT. Angiogenesis in malignant brain tumors. Oncologist. 2008; In press..
  25. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther. 2007 Nov; 7(11):1537-60.
    View in: PubMed
  26. Chi AS, Ryg P, Betensky R, Batchelor TT. Low-grade gliomas in older patients - a malignant tumor?. Neuro-Oncology. 2007; 9(4):467-602.
  27. Rost NS, Flaherty AW, Bruce BB, Chi AS, Cho T, Gilmore E, Norden AN, Sheth K. The Massachusetts General Hospital Handbook of Neurology. 2007.
  28. Chi AS, Wen PY. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets. 2007 Apr; 11(4):473-96.
    View in: PubMed
  29. Ma X, Renda MJ, Wang L, Cheng EC, Niu C, Morris SW, Chi AS, Krause DS. Rbm15 modulates Notch-induced transcriptional activation and affects myeloid differentiation. Mol Cell Biol. 2007 Apr; 27(8):3056-64.
    View in: PubMed
  30. Chi AS, Batchelor TT. Primary Brain Tumors. Harrison's Handbook of Medical Oncology. Chabner BA Lynch TJ, Longo DL, Editors. 2007; In press..
  31. Chi AS, Wen PY. Inhibiting Angiogenesis in Malignant Gliomas. Handbook of Neurology, Neuro-Oncology. Grisold W, Soffietti R, Editors. 2007.
  32. Chi A, Kesari S. POEMS Syndrome. MedLink Neurology. Gilman S, editor. 2006.
  33. Chi AS, Greer DM. Neurology Core Curriculum. 2005.
  34. Chi AS, Deng Z, Albach RA, Kemp RG. The two phosphofructokinase gene products of Entamoeba histolytica. J Biol Chem. 2001 Jun 8; 276(23):19974-81.
    View in: PubMed
  35. Chi A, Kemp RG. The primordial high energy compound: ATP or inorganic pyrophosphate? J Biol Chem. 2000 Nov 17; 275(46):35677-9.
    View in: PubMed
  36. Chi AS, Kemp RG. A Study of the Two Phosphofructokinases of Entamoeba histolytica. 1999.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Chi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_